Altered bone metabolism in inflammatory bowel disease

American Journal of Gastroenterology

Volumn 92, Issue 7, 1997, Pages 1157-1163

  Bischoff, Stephan C ^a   Herrmann, Annette ^a   Göke, Michael ^a   Manns, Michael P ^a   Von Zur Mühlen, Alexander ^a   Brabant, Georg ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; VITAMIN D;

ADOLESCENT; ADULT; ARTICLE; BONE DEFECT; BONE METABOLISM; CALCIUM BLOOD LEVEL; CARBOXY TERMINAL SEQUENCE; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; ENTERITIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; STEROID METABOLISM; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; COLITIS; COLITIS, ULCERATIVE; CROHN DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 0030835311     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Motley R, Crawley EO, Evans C, et al. Increased rate of spinal trabecular bone loss in patients with inflammatory bowel disease. Gut 1988;29:1332-6.
2. Clements D, Motley R, Evans WD, et al. Longitudinal study of cortical bone loss in patients with inflammatory bowel disease. Scand J Gastroenterol 1992;27:1055-60.
3. Gosh S, Cowen S, Hannan WJ, et al. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. Gastroenterology 1994;107:1031-9.
4. Abitol V, Roux C, Chaussade S, et al. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 1995;108: 417-22.
5. Silvennoinen J. Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease. J Intern Med 1996;239:131-7.
6. Compston JE, Judd D, Crawley EO, et al. Osteoporosis in patients with inflammatory bowel disease. Gut 1987;28:410-5.
7. Pigot F, Roux C, Chaussade S, et al. Low bone mineral density in patients with inflammatory bowel disease. Dig Dis Sci 1992;37:1396-403.
8. Vakil N, Sparberg M. Steroid-related osteonecrosis in inflammatory bowel disease. Gastroenterology 1989;96:62-7.
9. Silvennoinen JA, Karttunen TJ, Niemelä SE, et al. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995;37:71-6.
10. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumor necrosis factor-alpha, IL-6, and IL-1β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993;94:174-81.
11. Roodmann GD. Roles of cytokines in the regulation of bone resorption. Calcif Tissue Int 1993;53:S94-S98.
12. Stavros C, Manolagas MD, Jilka RL. Bone marrow, cytokines, and bone remodeling. N Engl J Med 1995;332:305-11.
13. Eyre D. New biomarkers of bone resorption. J Clin Endocrinol Metab 1992;74:470A-C.
14. Charles P, Hasling C, Risteli L, et al. Assessment of bone formation by biochemical markers in metabolic bone disease: Separation between osteoblastic activity at the cell and tissue level. Calcif Tissue Int 1992;51:406-11.
15. Delmas PD. Biochemical markers of bone turnover for the clinical assessment of metabolic bone disease. Endocrinol Metab Clin North Am 1990;19:1-9.
16. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. Gastroenterology 1976;70:439-44.
17. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulfasalazine in the treatment of active ulcerative colitis: A randomised trial. BMJ 1989;298:82-6.
18. Price PA, Nishimoto JK. Radioimmunoassay for the vitamin K-dependent protein of bone and its discovery in plasma. Proc Natl Acad Sci USA 1980;77:2234-8.
19. Podenphant J, Christiansen C, Catherwood BD, et al. Serum bone Gla Protein and other biochemical estimates of bone turnover in early postmenopausal women during prophylactic treatment for osteoporosis. Acta Med Scand 1985;218:329-33.
20. Melkko J, Niemi S, Risteli L, et al. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 1990;36:1328-32.
21. Risteli J, Elomaa I, Niemi S, et al. Radioimmunoassay for the pyridinoline cross-linked carboxyterminal telopeptide of type I collagen: A new serum marker of bone collagen degradation. Clin Chem 1993; 39:635-40.
22. Elomaa I, Virkkunen P, Risteli J. Serum concentrations of cross-linked carboxyterminal telopeptide of type I collagen (ICIP) is a useful prognostic indicator in multiple myeloma. Br J Cancer 1992;66:337-41.
23. Wapniarz M, Lehmann R, Randerath O, et al. Precision of dual x-ray absorptiometry and peripheral computed tomography using mobile densitometry units. Calcif Tissue Int 1994;54:219-23.
24. Butz S, Wüster C, Scheidt-Nave C, et al. Forearm BMD as measured by peripheral quantitative computed tomography (pQCT) in a German reference population. Osteoporos Int 1994;4:179-84.
25. Scharla SH, Minne HW, Lempert UG, et al. Bone mineral density and calcium regulating hormones in patients with inflammatory bowel disease (Crohn's disease and ulcerative colitis). Exp Clin Endocrinol 1994;102:44-9.
26. Silvennoinen J, Risteli L, Karttunen T, et al. Increased degradation of type I collagen in patients with inflammatory bowel disease. Gut 1996;38:223-8.
27. Burgeson RE. New collagens, new concepts. Annu Rev Cell Biol 1988;4:551-77.
28. Robins SP. Turnover and crosslinking of collagen. In Weiss JB, Jayson MIV, eds. Collagen in health and disease. Edinburgh: Churchill Livingstone, 1982:160-78.
29. Azria M. The value of biomarkers in detecting alterations in bone metabolism. Calcif Tissue Int 1989;45:7-11.
30. Harvey RD, McHardy KC, Reid IW, et al. Measurement of bone collagen degradation in hyperthyroidism and during thyroxin replacement therapy using pyridinium cross-links as specific urinary markers. J Clin Endocrinol Metab 1991;72:1189-94.
31. Eriksen EF, Charles P, Melsen F, et al. Serum markers of type I collagen formation and degradation in metabolic bone disease: Correlation to bone histomorphometry. J Bone Miner Res 1993;8:127-33.
32. Kylmälä T, Tammala T, Risteli L, et al. Evaluation of the effect of oral clodronate on skeletal metastases with type I collagen metabolites: A controlled trial of the Finish prostate cancer group. Eur J Cancer 1993;29A:821-5.
33. Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983;309:265-8.
34. Dykman TR, Gluck OS, Murphy WA, et al. Evaluation of factors associated with glucocorticoid-induced osteopenia with rheumatic diseases. Arthritis Rheum 1985;28:361-8.
35. Freeman HJ, Kwan WCP. Non-corticosteroid-associated osteonecrosis of the femoral heads in two patients with inflammatory bowel disease. N Engl J Med 1993;329:1314-6.
36. Pistorius LR, Sweidan WH, Purdie DW, et al. Coeliac disease and bone mineral density in adult female patients. Gut 1995;37:639-42.
37. Walters JRF, Banks LM, Butcher GP, et al. Detection of low bone mineral density by dual energy x-ray absorptiometry in unsuspected suboptimally treated coeliac disease. Gut 1995;37:220-4.
38. Clements D, Compston JE, Evans WD, et al. Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. Gut 1993;34:1543-6.
39. Jowell PS, Epstein S, Fallon MD, et al. 1,25-dihydroxyvitamin D3 modulates glucocorticoid-induced alteration in serum bone Gla protein and bone histomorphometry. Endocrinology 1987;120:531-6.